RVRandy Vince

Randy Vince

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Randy Vince has a total of 248 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials

    by Georges Gebrael, Neeraj Agarwal, Alicia K. Morgans, Randy Vince, Umang Swami, Angela Y. Jia, Nicholas Zaorsky, Chadi Hage Chehade, Zeynep Irem Ozay, Shawn Malone, et al.

    Background: Clinical studies have shown that outcomes of patients with prostate cancer could vary depending on race. In this study, the authors sought to determine if the treatment effect of apalutamide, an androgen receptor pathway inhibitor (ARPI), on overall survival (OS) varies depending on the race of the patient. Methods: This pooled analysis includes individual patient data from two phase 3 trials, TITAN and SPARTAN, which randomized patients to androgen deprivation therapy (ADT) ± apalutamide in metastatic hormone‐sensitive and nonmetastatic castration‐resistant prostate cancer, respectively. Race was self‐identified and categorized as Asian, Black, White, and Others categories. The authors applied a stratified (stratification for the trial) multivariable Cox proportional hazards regression model to determine heterogeneity of treatment effect on OS after adjustment for age, performance status, body mass index, T‐ and N‐stage, Gleason score, comorbidities, and exposure to statins and metformin. Results: Overall, 2190 patients were included: 16.9% patients were Asian, 3.7% were Black, 67.4% were White, and 12.0% were from the Others category. The authors did not find any significant heterogeneity of treatment effect from apalutamide on OS across racial groups (interaction‐ p = .46). Among ADT plus apalutamide‐treated patients, there was no association of race with OS (hazard ratio for Asian, 0.77 [95% CI, 0.56–1.06]; Black, 0.82 [95% CI, 0.49–1.37]; and Others, 1.00 [95% CI, 0.75–1.34], all compared to White). Conclusions: In this study, the authors did not find any evidence of difference in the treatment effect of apalutamide on OS across patients of different races, although interpretation remains limited by poor representation of racial minorities. Among apalutamide‐treated patients, there was no association of race with OS.

  • Association between County Health Rankings Factors and County-level Genitourinary Cancer Mortality

    by Jad Badreddine, Erin Kim, Stephen Tang, Stephen Rhodes, Laura Davis, Holly Hartman, Jennifer Cullen, Johnie Rose, Randy Vince

    To explore the association between County Health Ranking (CHR) factors, county-level demographics, and county-level age-adjusted genitourinary (GU) cancer mortality rates. This population-based study used county-level data from the US and CHR program. CHR bases county-level scoring on four factors: health behaviors, clinical care, social and economic factors, and physical environment-higher values per factor signify a better score. The relationship between county-level factors, demographics, and age-adjusted GU-cancer mortality rates was analyzed with linear mixed-effects models. We included interaction terms between the county-level factors and the proportion of Black residents. County-level variables associated with lower age-adjusted GU-cancer mortality rates included larger population (beta/SD increase: - 0.64; 95% CI, - 0.82 to - 0.4, P < 0.001), positive health behaviors (- 0.58; 95% CI, - 0.83 to - 0.33, P < 0.001), and clinical care (- 0.21; 95% CI, - 0.41 to - 0.01, P = 0.04). A higher proportion of Black residents was associated with increasing age-adjusted GU-cancer mortality rate (0.52; 95% CI, 0.28-0.75, P < 0.001). Interaction terms demonstrated a relationship between clinical care and age-adjusted GU-cancer mortality rates that was attenuated by the proportion of Black residents (interaction-beta: 0.24; 95% CI, 0.06-0.42, P = 0.01). Follow-up analysis of clinical care demonstrated that quality of care, not access, was associated with decreased mortality rates. The beneficial association between better clinical care and decreased age-adjusted GU-cancer mortality rates was modulated by the proportion of Black residents and appears due to the healthcare access sub-component. These findings suggest that having healthcare resources within a county does not ensure equitable access to high-quality healthcare, specifically for Black residents. Classification code: 9760.

  • Open Access

    Individual income and race-associated differences in prostate cancer mortality in a statewide registry

    by Alec Zhu, Stephen Rhodes, Bashir Al Hussein Al Awamlh, Randy A Vince, Nicholas Zaorsky, Daniel E Spratt, Camilo Arenas Gallo, Anyull Dayanna Bohorquez Caballero, Mollie Goldman, Jonathan E Shoag

    Background: Prior studies evaluating racial disparities in cancer outcomes used regional measures of deprivation when accounting for socioeconomic status, which lack granularity. We evaluated differences in prostate cancer mortality between Black and White men using individual home prices in addition to regional metrics to understand the impact of individual wealth on prostate cancer outcomes. Methods: Individuals diagnosed with prostate cancer between January 2004 and December 2016 in the Ohio Cancer Incidence Surveillance System were included. Individual home addresses were linked to the Area Deprivation Indices and home prices using data from an online real estate marketplace. Using inverse probability weighting to balance patient characteristics, we assessed differences in prostate cancer–specific mortality or other-cause mortality between Black and White men after accounting for clinical characteristics and social determinants of health (insurance, area deprivation, and home price). Results: We identified 70 660 (85%) White and 12 192 (15%) Black men with prostate cancer. Black race was associated with a higher risk of prostate cancer–specific mortality in models that adjusted for age and year at diagnosis (subdistribution hazard ratio = 1.45, 95% CI = 1.45 to 1.57) and with the addition of cancer variables (subdistribution hazard ratio = 1.16, 95% CI = 1.06 to 1.26). In models that incorporate social determinants of health, however, rates of prostate cancer–specific mortality and other-cause mortality were not statistically significantly higher for Black men (subdistribution hazard ratios = 1.10, 95% CI = 0.98 to 1.24, and 1.02, 95% CI = 0.95 to 1.09), respectively. Conclusions: After accounting for clinical characteristics and social determinants of health at the individual level, Black men were not at increased risk of prostate cancer mortality relative to White men.

  • Open Access

    Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?

    by Albert Jang, Nikita Tripathi, Sree M Lanka, Hamsa L S Kumar, Prateek Jain, Adam Calaway, Jonathan E Shoag, Randy Vince, Prateek Mendiratta, Santosh Rao, et al.

    The combination of enfortumab vedotin and pembrolizumab (EVP) has recently revolutionized care for patients with previously untreated locally advanced and metastatic urothelial carcinoma. However, predictive biomarkers of response, the optimal duration of EVP for patients who respond well to therapy, and the role of circulating tumor DNA to monitor treatment response have not yet been fully elucidated. In this molecular tumor board, we summarize 6 patients from 4 different academic institutions with unresectable or oligometastatic urothelial carcinoma who achieved long-term remission on surveillance after a short duration of EVP treatment that resulted in complete response on follow-up imaging followed by consolidative radical cystectomy. We discuss potential predictive biomarkers for patients with exceptional response to EVP. These findings highlight the need to determine an optimal duration of EVP to maximize efficacy while minimizing adverse events. We aim to further define and explore the value of local therapy with consolidative cystectomy in the setting of unresectable, locally advanced, oligometastatic disease, or those with metastatic disease who achieve complete response of disease outside of the bladder. Identifying this subset of patients who may be candidates for this type of multidisciplinary management may result in durable treatment-free remission.


  • Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 Men

    by Angela Y. Jia, Yilun Sun, Maitry Patel, Atallah Baydoun, Randy A. Vince, Jonathan E. Shoag, Jason R. Brown, Pedro C. Barata, Matthew J. Schipper, Robert T. Dess, et al.

    PURPOSE: The 22-gene Decipher genomic classifier (GC) (22-gene GC) is the only gene expression test with National Comprehensive Cancer Network (NCCN) level 1 evidence for localized prostate cancer (PCa) treatment decision making. It is unclear whether other commercial signatures—Genomic Prostate Score (GPS) or Prolaris (cell cycle progression [CCP])—correlate sufficiently to explain differences in evidence strength. This study assesses correlation between these three classifiers on a per-patient basis by performing a cross-comparison of these signatures in a large cohort of patients diagnosed with PCa. MATERIALS AND METHODS: Primary PCa biopsy samples underwent whole-transcriptome gene expression microarray analysis. 22-gene GC scores were calculated using the commercially locked model. To reduce bias, GPS and CCP signatures were retrained for prediction of metastasis to harmonize end points. Pearson correlations and linear regressions (univariable/multivariable) adjusting for age, grade group, prostate-specific antigen (PSA), and T stage were calculated between signatures. RESULTS: Among 50,881 patients (median age 68 years, median PSA 6.2 ng/mL), 60% were NCCN intermediate-risk. The GPS-derived and CCP-derived models had poor goodness-of-fit to 22-gene GC ( R 2 = 0.36 and 0.32, respectively). Multivariable analysis adjusting for clinical factors showed similar results. Given the many variables that may contribute to or correlate with the 22-gene GC, a multivariable R 2 analysis was performed to assess how much of the variation could be attributed to known factors. A variance analysis revealed approximately 60% of 22-gene GC variation remained unexplained. GPS-derived and CCP-derived models accounted for 24.7% and 22.7% of variance, respectively, with additional contributions from Gleason score. CONCLUSION: Correlation between 22-gene GC and either GPS-derived or CCP-derived signatures is minimal to moderate. These tests are not interchangeable, and their use should be guided by the specific evidence supporting each signature.


  • Does Complexity and Racialization Limit PSA Screening?

    by Randy A. Vince, Camilo Arenas-Gallo, Peter J. Pronovost

  • Assessing the Clinical Utility of Published Prostate Cancer Polygenic Risk Scores in a Large Biobank Data Set

    by Randy A. Vince, Helen Sun, Udit Singhal, Fredrick R. Schumacher, Erika Trapl, Johnie Rose, Jennifer Cullen, Nicholas Zaorsky, Jonathan Shoag, Holly Hartman, et al.


  • Prostate Cancer Foundation Screening Guidelines for Black Men in the United States

    by Isla P. Garraway, Sigrid V. Carlsson, Yaw A. Nyame, Jason L. Vassy, Marina Chilov, Mark Fleming, Stanley K. Frencher, Daniel J. George, Adam S. Kibel, Sherita A. King, et al.

    In the United States, Black men are at highest risk for being diagnosed with and dying from prostate cancer. Given this disparity, we examined relevant data to establish clinical prostate-specific antigen (PSA) screening guidelines for Black men in the United States. A comprehensive literature search identified 1848 unique publications for screening. Of those screened, 287 studies were selected for full-text review, and 264 were considered relevant and form the basis for these guidelines. The numbers were reported according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Three randomized controlled trials provided Level 1 evidence that regular PSA screening of men 50 to 74 years of age of average risk reduced metastasis and prostate cancer death at 16 to 22 years of follow-up. The best available evidence specifically for Black men comes from observational and modeling studies that consider age to obtain a baseline PSA, frequency of testing, and age when screening should end. Cohort studies suggest that discussions about baseline PSA testing between Black men and their clinicians should begin in the early 40s, and data from modeling studies indicate prostate cancer develops 3 to 9 years earlier in Black men compared with non-Black men. Lowering the age for baseline PSA testing to 40 to 45 years of age from 50 to 55 years of age, followed by regular screening until 70 years of age (informed by PSA values and health factors), could reduce prostate cancer mortality in Black men (approximately 30% relative risk reduction) without substantially increasing overdiagnosis. These guidelines recommend that Black men should obtain information about PSA screening for prostate cancer. Among Black men who elect screening, baseline PSA testing should occur between ages 40 and 45. Depending on PSA value and health status, annual screening should be strongly considered. (Supported by the Prostate Cancer Foundation.).


  • Open Access

    Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype

    by Mark Farha, Srinivas Nallandhighal, Randy Vince, Brittney Cotta, Judith Stangl-Kremser, Daniel Triner, Todd M. Morgan, Ganesh S. Palapattu, Marcin Cieslik, Ulka Vaishampayan, et al.

    There is a need to optimize the treatment of clear cell renal cell carcinoma (ccRCC) patients at high recurrence risk after nephrectomy. We sought to elucidate the tumor immune microenvironment (TIME) of localized ccRCC and understand the prognostic and predictive characteristics of certain features. The discovery cohort was clinically localized patients in the TCGA-Kidney Renal Clear Cell Carcinoma (KIRC) project (n = 382). We identified an M0 macrophage-enriched cluster (n = 25) in the TCGA-KIRC cohort. This cluster’s median progression-free survival (PFS) and overall survival (OS) were 40.4 and 45.3 months, respectively, but this was not reached in the others (p = 0.0003 and n = 9) with shorter PFS (p = 0.0006) was also identified in the Clinical Proteomics Tumor Analysis Consortium (CPTAC) cohort (n = 94). Through this characterization of the TIME in ccRCC, a cluster of patients defined by enrichment in M0 macrophages was identified that demonstrated poor prognosis and lower predicted ICB response. Pending further validation, this signature can identify localized ccRCC patients at high risk of recurrence after nephrectomy and who may require therapeutic approaches beyond ICB monotherapy.